
About this episode
This episode takes a deep dive into Tesamorelin, a synthetic peptide that stimulates growth hormone release and has been FDA approved for reducing visceral fat in patients with HIV-associated lipodystrophy. Listeners will learn how Tesamorelin works, its effects on growth hormone and IGF-1, and why it stands out compared to other peptides. The discussion explores its impact on body composition, metabolic health, and liver fat, as well as potential off-label uses in obesity, fatty liver disease, and anti-aging research. Side effects, safety considerations, and long-term questions are also covered, giving you a balanced and accessible understanding of this unique peptide therapy.
Get every episode summarized
Each time The Peptide Effect publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Peptide Effect

The Hidden GLP-1 Switch: How These Drugs May Reprogram Pancreatic Cells
The Peptide Effect

The Science of Peptide-Based Myostatin Inhibitors: Can We Unlock More Muscle?
The Peptide Effect

Apolipoprotein-Targeting Peptides: The Future of Cholesterol, Brain Health, and...
The Peptide Effect

Border Seizures and the Peptide Market: What’s Happening to Supply, Pricing, and...
The Peptide Effect